143 related articles for article (PubMed ID: 37786611)
21. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial.
Powles T; Csőszi T; Özgüroğlu M; Matsubara N; Géczi L; Cheng SY; Fradet Y; Oudard S; Vulsteke C; Morales Barrera R; Fléchon A; Gunduz S; Loriot Y; Rodriguez-Vida A; Mamtani R; Yu EY; Nam K; Imai K; Homet Moreno B; Alva A;
Lancet Oncol; 2021 Jul; 22(7):931-945. PubMed ID: 34051178
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of pembrolizumab in combination with S-1 plus oxaliplatin as a first-line treatment in patients with advanced gastric/gastroesophageal junction cancer: Cohort 1 data from the KEYNOTE-659 phase IIb study.
Kawazoe A; Yamaguchi K; Yasui H; Negoro Y; Azuma M; Amagai K; Hara H; Baba H; Tsuda M; Hosaka H; Kawakami H; Oshima T; Omuro Y; Machida N; Esaki T; Yoshida K; Nishina T; Komatsu Y; Han SR; Shiratori S; Shitara K
Eur J Cancer; 2020 Apr; 129():97-106. PubMed ID: 32145474
[TBL] [Abstract][Full Text] [Related]
23. First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study.
Makiyama A; Kunieda K; Noguchi M; Kajiwara T; Tamura T; Takeda K; Sugiyama J; Minashi K; Moriwaki T; Sugimoto N; Nagase M; Negoro Y; Tsuda T; Shimodaira H; Okano N; Tsuji A; Sakai D; Yanagihara K; Ueda S; Tamura S; Otsu S; Honda T; Matsushita Y; Okuno T; Kashiwada T; Nozaki A; Ebi M; Okuda H; Shimokawa M; Hironaka S; Hyodo I; Baba E; Boku N; Muro K; Esaki T
Gastric Cancer; 2018 Sep; 21(5):792-801. PubMed ID: 29353332
[TBL] [Abstract][Full Text] [Related]
24. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Herbst RS; Arkenau HT; Santana-Davila R; Calvo E; Paz-Ares L; Cassier PA; Bendell J; Penel N; Krebs MG; Martin-Liberal J; Isambert N; Soriano A; Wermke M; Cultrera J; Gao L; Widau RC; Mi G; Jin J; Ferry D; Fuchs CS; Petrylak DP; Chau I
Lancet Oncol; 2019 Aug; 20(8):1109-1123. PubMed ID: 31301962
[TBL] [Abstract][Full Text] [Related]
25. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
[No Abstract] [Full Text] [Related]
26. Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study.
Zhang L; Zhang J; Wang Y; Li W; Yu S; Li Q; Yu Y; Liu T; Cui Y
BMC Gastroenterol; 2022 Jun; 22(1):296. PubMed ID: 35701768
[TBL] [Abstract][Full Text] [Related]
27. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard L; Dinart D; Delaunay B; Fléchon A; Saldana C; Lefort F; Gravis G; Thiery-Vuillemin A; Cancel M; Coquan E; Ladoire S; Maillet D; Rolland F; Boughalem E; Martin S; Laramas M; Crouzet L; Abbar B; Falkowski S; Pouessel D; Roubaud G
Eur J Cancer; 2022 Nov; 175():43-53. PubMed ID: 36088671
[TBL] [Abstract][Full Text] [Related]
29. Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen.
Bozkaya Y; Erdem GU; Özdemir NY; Hocazade C; Yazici O; Demirci NS; Zengin N
J Cancer Res Ther; 2018 Sep; 14(Supplement):S742-S747. PubMed ID: 30249897
[TBL] [Abstract][Full Text] [Related]
30. Treatment Patterns and Outcomes in Chinese Patients with Gastric Cancer by HER2 Status: A Noninterventional Registry Study (EVIDENCE).
Qin S; Ji J; Xu RH; Wang W; Tang Y; Bi F; Li J; Wang K; Xu JM; Fan Q; Su W; Shen L
Oncologist; 2021 Sep; 26(9):e1567-e1580. PubMed ID: 34003545
[TBL] [Abstract][Full Text] [Related]
31. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study.
Qian DC; Kleber T; Brammer B; Xu KM; Switchenko JM; Janopaul-Naylor JR; Zhong J; Yushak ML; Harvey RD; Paulos CM; Lawson DH; Khan MK; Kudchadkar RR; Buchwald ZS
Lancet Oncol; 2021 Dec; 22(12):1777-1786. PubMed ID: 34780711
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of radiotherapy in combination with first-line immunotherapy and chemotherapy for advanced lung squamous cell carcinoma: a propensity score analysis.
Qin J; Yi S; Zhou H; Zeng C; Zou M; Zeng X; Yang Z; Huang Y
Front Immunol; 2023; 14():1138025. PubMed ID: 37261356
[TBL] [Abstract][Full Text] [Related]
33. A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y; Ji M; Jiang Y; Yin R; Wang Z; Li H; Wang S; He K; Ma Y; Wang Z; Lu J; Shi M; Shen B; Zhou G; Leong TL; Wang X; Chen C; Feng J
Transl Lung Cancer Res; 2022 Jun; 11(6):1051-1068. PubMed ID: 35832459
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy
Li Y; Ma FH; Xue LY; Tian YT
World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
[TBL] [Abstract][Full Text] [Related]
35. [Safety and efficacy of laparoscopic surgery in locally advanced gastric cancer patients with neoadjuvant chemotherapy combined with immunotherapy].
Lv JB; Yin YP; Zhang P; Cai M; Chen JH; Li W; Li G; Wang Z; Wang GB; Tao KX
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 Jan; 26(1):84-92. PubMed ID: 36650004
[No Abstract] [Full Text] [Related]
36. Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L).
Kato R; Hayashi H; Chiba Y; Miyawaki E; Shimizu J; Ozaki T; Fujimoto D; Toyozawa R; Nakamura A; Kozuki T; Tanaka K; Teraoka S; Usui K; Nishino K; Hataji O; Ota K; Ebi N; Saeki S; Akazawa Y; Okuno M; Yamamoto N; Nakagawa K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32066647
[TBL] [Abstract][Full Text] [Related]
37. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
[TBL] [Abstract][Full Text] [Related]
38. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
[TBL] [Abstract][Full Text] [Related]
39. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
40. Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis.
Wu L; Feng Y; Wu Z; Xu H; Zhang C; Ning J; Wang R; Chen J; Xie M; Zhang Y; Bu L; Hao J; Ma T
World J Surg Oncol; 2021 Sep; 19(1):272. PubMed ID: 34507562
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
